Oral VK2735 for Weight Management Phase 3 (SUNRISE 1)
NCT07868835 on ClinicalTrials.gov · last registry update 2026-10-16
Registered but not yet open, with 560 participants planned. Due to report July 2028, alongside 23 other tracked readouts that quarter. Primary outcome, as filed: Percentage change in body weight for participants receiving VK2735 orally once daily. Sponsors move these dates routinely; any movement since this site started watching is listed below. VK2735 is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended. The registry entry has been edited 1 time since then.
- Status
- NOT_YET_RECRUITING
- Phase
- P3
- Drug
- VK2735
- Sponsor
- Viking Therapeutics, Inc.
- Sponsor type
- Industry
- Enrollment
- 560
- Started
- 2026-11
- Primary completion
- 2028-07 estimated
Observed history
Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.
| Detected | Change | Detail |
|---|---|---|
| 2026-10-09 | First seen in registry | Registered as NOT_YET_RECRUITING, P3 |
Primary outcome
Percentage change in body weight for participants receiving VK2735 orally once daily
Conditions studied
Weight Loss
Every field above is taken directly from the registry record. See all detected changes across the class, or the VK2735 page for this molecule’s full trial and approval history.